Ocular's lead product fails in second PhIII
This article was originally published in Scrip
Executive Summary
Ocular Therapeutix's sank on 7 April following mediocre results from a second Phase III trial of the company's lead product candidate, OTX-DP (sustained release dexamethasone).
You may also be interested in...
Regeneron Partnering With Ocular May Provide Needed Tech Validation
Regeneron is partnering with the troubled ophthalmology-focused biotech to develop a sustained-release formulation of Eylea that could enable a less-frequent dosing regimen.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.